Bofutrelvir - Frontier Biotechnologies
Alternative Names: DC-402234; FB-2001Latest Information Update: 28 Apr 2024
At a glance
- Originator Frontier Biotechnologies
- Class Amides; Antivirals; Indoles; Pyrrolidinones; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections in USA (IV, Infusion)
- 04 Jan 2023 Phase-II/III clinical trials in COVID-2019 infections in China (Inhalation) (NCT05675072)
- 30 Dec 2022 Frontier Biotechnologies completes a phase I trial in COVID-2019 infections in China (Inhalation) (NCT05583812)